Direkt zum Inhalt
Merck

MAB348-AF555

Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, Alexa Fluor 555

clone 22C11, from mouse, ALEXA FLUOR 555

Synonym(e):

Amyloid beta A4 protein, ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II, PN-II, N-APP, Soluble APP-alpha, S-APP-alpha, Soluble APP-beta, S-APP-beta,

Anmelden Preise für Organisationen und Verträge anzeigen

Größe auswählen


Über diesen Artikel

UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Biologische Quelle

mouse

Qualitätsniveau

Konjugat

ALEXA FLUOR 555

Antikörperform

purified immunoglobulin

Antikörper-Produkttyp

primary antibodies

Klon

22C11, monoclonal

Speziesreaktivität

canine, human, mouse, rat, porcine, monkey, fish

Methode(n)

immunocytochemistry: suitable

Isotyp

IgG1

NCBI-Hinterlegungsnummer

UniProt-Hinterlegungsnummer

Versandbedingung

wet ice

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... APP(351)

Allgemeine Beschreibung

Amyloid beta A4 protein (UniProt P05067; also known as ABPP, Alzheimer disease amyloid protein, Amyloid precursor protein, APP, APPI, Cerebral vascular amyloid peptide, CVAP, PN-II, PreA4, Protease nexin-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID 351) in human. Amyloid precursor protein (APP) is initially produced with a signal peptide sequence (a.a. 1-17), the removal of which yields the mature protein with a large extracellular portion (a.a. 18-699), followed by a transmembrane segment (a.a. 700-723) and a cytoplasmic (a.a. 724-770) tail. APP can be further processed by the α-, β-, and γ-secretases in two alternative processing pathways. In the non-amyloidogenic pathway, APP is first cleaved by the plasma membrane-localized α-secretase to generate an N-terminal extracellular sAPPα fragment (a.a. 18-687) and a membrane-bound C-terminal fragment C83 (CTFα), which can be further cleaved by γ-secretase to produce a non-toxic small peptide p3 and a cytoplasmic APP intracellular domain (AICD). In the amyloidogenic pathway, APP undergoes β-cleavage in BACE-1 (β-site APP-cleaving enzyme)-enriched endosomes to generate an N-terminal extracellular sAPPβ fragment (a.a. 18-671) and a membrane-bound C-terminal fragment C99 (CTFβ). Subsequent cleavage of C99 by γ-secretase releases the amyloid β peptide (Aβ) and AICD. Aβ accumulation in the cortical and hippocampal regions of the brain is a major pathological feature of Alzheimer′s disease (AD).
~110/120/130 kDa observed.

Immunogen

Epitope: Amino acids 66-81 of APP.
Purified recombinant Alzheimer precursor A4 (pre-A4695) fusion protein.

Anwendung

Research Category
Neurowissenschaft
Research Sub Category
Neurodegenerative Krankheiten
Anti-APP A4 Antibody, a.a. 66-81 of APP {NT}, clone 22C11, Alexa Fluor 555 is an antibody against APP A4 for use in Immunocytochemistry.
The unconjugated antibody (Cat. No. MAB348) is shown to be suitable also for immunohistochemistry (for both frozen and paraffin-embedded sections), immunofluorescence, and Western blotting applications.

Biochem./physiol. Wirkung

Clone 22C11 reacts with pre-A4. The antibody recognizes amino acids 66-81 of the N-terminus on the pre-A4 molecule (Hilbich, C., et al. (1993). J. Biol. Chem. 268(35):26571-26577). Clone 22C11 recognizes all three isoforms of APP, immature ~110kDa, sAPP ~120kDa, and mature ~130kDa (Hoffmann, J., et al. (2000). Eur. J. Cell. Biol.79(12):905-914.). The antibody is known to cross react with APLP2 (Slunt, H.H., et al. (1994). J. Biol. Chem. 269(4):2637-2644).

Physikalische Form

Protein A purified
Purified mouse monoclonal IgG1 antibody conjugate in PBS with 15 mg/mL BSA and 0.1 % sodium azide.

Angaben zur Herstellung

Stable for 1 year at 2-8°C from date of receipt.

Hinweis zur Analyse

Evaluated by Immunocytochemistry in SH-5YSY cells.

Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected APP A4 in SH-5YSY cells.

Sonstige Hinweise

Concentration: Please refer to lot specific datasheet.

Rechtliche Hinweise

ALEXA FLUOR is a trademark of Life Technologies

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Verwandter Inhalt

Alzheimer’s Disease is a progressively deteriorating disease. It manifests itself with memory loss, confusion, problems with judgment, planning, concentration, and personality changes; and in it’s later stages, a decline in physical abilities. The disease’s causes, cures, and preventions are unknown; however, key proteins likely involved in the degenerative mechanism have been identified. Alzheimer’s Disease is characterized by neuronal loss, alterations in neurotransmitter systems, and the presence of neurofibrillary tangles composed of abnormally hyperphosphorylated tau proteins. A prominent feature of Alzheimer’s Disease is the formation of senile plaques in selected regions of the brain. The center of these plaques are composed mainly of fibrillary aggregates of a common, but not well understood, b amyloid peptides (Aβ). The Aβ peptides are generated from the larger amyloid-β precursor protein (APP) by the sequential action of β- and γ-secretase, and it is generally accepted that oligomeric forms of this Aβ are neurotoxic, resulting in disease progression.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung